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Schizophrenia is a chronic and disabling mental illness aﬀecting millions of people worldwide. A greater proportion of people
with schizophrenia tends to be overweight. Antipsychotic medications have been considered the primary risk factor for obesity
in schizophrenia, although the mechanisms by which they increase weight and produce metabolic disturbances are unclear.
Several lines of research indicate that leptin could be a good candidate involved in pathways linking antipsychotic treatment
and weight gain. Leptin is a circulating hormone released by adipocytes in response to increased fat deposition to regulate body
weight, acting through receptors in the hypothalamus. In this work, we reviewed preclinical, clinical, and genetic data in order
to infer the potential role played by leptin in antipsychotic-induced weight gain considering two main hypotheses: (1) leptin is
an epiphenomenon of weight gain; (2) leptin is a consequence of antipsychotic-induced “leptin-resistance status,” causing weight
gain.
1.Background
Schizophrenia has a worldwide prevalence of about one per-
cent and has the potential for devastating emotional, phys-
ical, and mental consequences [1]. Antipsychotic drugs are
the ﬁrst line of treatment for those with schizophrenia and
other psychoses [2]. There are two classes of antipsychotic
medications used for treatment referred to as either typical
or atypical. Typical antipsychotic drugs, like haloperidol, act
as high-aﬃnity antagonists for dopamine 2 (D2) receptors
with a possibility of extrapyramidal side eﬀects.
Second-generation antipsychotics (SGAs), like olanzap-
ine and clozapine, have lower incidences of extrapyramidal
side eﬀects than typical antipsychotics because they are po-
tent antagonists of serotonin 2A (5-HT2A) rather than D2
receptor antagonists, with a higher aﬃnity for the former.
These drugs also inhibit the G-protein-coupled receptors for
severalotherbiogenicaminesincludingcholinergic,adrener-
gic (α), histaminergic (H), and dopaminergic receptors [3].
The increased use of atypical antipsychotics over the last
decade has raised concerns about their metabolic side eﬀects,
such as weight gain, diabetes, and dyslipidemia [4]. In ad-
dition, medication-induced weight gain has been associated
with a lower quality of life and noncompliance, which in-
creases the risk for relapse. The higher risk of cardiovascular
disease, leading to enhanced morbidity, mortality, signiﬁcant
economic cost, reduced quality of life, and lower compliance
to treatment can be linked to the obesitogenic and diabeto-
genic capacity of these drugs [5].
However, the mechanisms of weight gain and dyslipi-
demia are poorly understood, and various parts of the en-
docrine system are presumably involved in these side eﬀects.
Several lines of evidence indicate that antipsychotic drugs
elicit weight gain in some, but not all, individuals, suggesting
a genetic predisposition [5]. Several hypotheses with regard
to the biological mechanism underlying diﬀerential genetic
liability have been suggested, mostly linked to genes which2 Journal of Obesity
regulate appetite and food intake caused by SGA-induced
stimulation of 5-HT1A and 5-HT6 receptors, as well as α2
and muscarinic M3 receptors. Additionally, blocking recep-
tors such as the 5-HT2C, 5-HT1B, α1, H1 are known to result
in additional weight gain [6–9].
Not surprisingly, hyperphagia is associated with weight
gain in humans. Accordingly, it has been demonstrated that
olanzapine-induced weight gain is caused by increased
caloricintake,ratherthanalterationsinbasalenergyexpend-
iture [10]. It has been suggested that antipsychotics interact
with the complex system of neurotransmitters, neuropep-
tides, and other modulators in brain neuronal circuits in-
volving the hypothalamus and brain stem where a neuropep-
tidergic network mediates the actions of leptin and ghrelin
to provoke disturbances in energy homeostasis, endocrine
alterations, and body weight (BW) control [11].
Recent studies have shown that the hormones leptin and
ghrelin are crucial elements of the hypothalamic neurocir-
cuitry. Leptin, a 16kD peptide, is a cytokine-like molecule
synthesizedinwhiteadiposetissue[12–14].Leptinisahighly
hydrophilic 167 amino acid protein and it is transported
across the blood brain barrier by binding to the short form
of the leptin receptor [14, 15] and is actively transported into
the hypothalamus, where it acts to limit food intake. It is a
product of the obese (OB) gene located on chromosome 7
(7q31.3). Receptors for leptin are widely expressed through-
out the central nervous system (CNS), but the major target
of this hormone is the medial hypothalamus [16]. Although
the leptin receptor is present as diﬀerent splice-variant iso-
forms in the CNS, the form OBRb has the major role in
its metabolic action [12, 16]. The obese db/db mouse and
Zucker fa/fa rat represent naturally occurring “knockouts”
of the leptin receptor, that have helped to validate the im-
portance of CNS leptin action in energy homeostasis [17].
Exogenous leptin reduces appetite and feeding while leptin
deﬁciency (both mice and humans with mutations in the
leptingene)causesextremeobesityandcanleadtoreproduc-
tiveproblems,boneformationdeﬁciency,andcardiovascular
complications [18–22]. It appears more involved in long-
term regulation of energy, being released into the circulatory
system as a function of energy stores.
In particular, leptin has multiple eﬀects on energy ho-
meostasis through activation of key hypothalamic nuclei and
peptides to regulate energy balance. Leptin directly activates
proopiomelanocortin (POMC) cells in the arcuate nucleus
(ARC) to increase the release of melanocortin peptides in-
cluding the POMC product α-melanocyte-stimulating hor-
mone (α-MSH). Melanocortin peptides inhibit food intake
and regulates metabolism via energy storage, insulin secre-
tion, and gastrointestinal motility predominantly through
projections to MC4 receptor neurons [23–28].
Moreover, leptin also directly inhibits ARC, which pro-
duces agouti-related protein and neuropeptide Y. Hypotha-
lamic ARC neurons—referred to as “ﬁrst-order” neurons—
receive signals from the blood via the median eminence, and
from the cerebrospinal ﬂuid (CSF) via the third ventricle.
The ARC contains two populations of neurons particu-
larly relevant to feeding and satiety; the neuropeptide Y
(NPY)/agoutirelated protein (AgRP) neurons and the pro-
opiomelanocortin (POMC)/cocaine- and amphetamine-re-
lated transcript (CART) neurons [25, 26]. These two groups
of neurons interact with “second-order” neurons in other
hypothalamic regions such as the paraventricular nucleus
(PVN), dorsomedial hypothalamus (DMH), ventrome-
dial hypothalamus (VMH), and lateral hypothalamic area
(LHA).
Another key region implicated in research pertaining
to weight and energy homeostasis is the caudate putamen
(CPu).
Dopamine (DA) neurons in the CPu have been shown
to play a role in maintaining food intake and hunger levels
[29–33]. Indeed, imaging studies have shown that severely
obese individuals have decreased striatal D2 receptor (D2R)
availability, and leptin-receptor-deﬁcient obese rodents also
show decreased D2R binding in striatum [34, 35]. In con-
trast, chronic food restriction showed greater striatal D2R
binding relative to ad libitum fed rats [35–37]. Genetic
studies, although not always consistent, have reported that
individuals carrying the Taq I A1 allele of the D2R gene,
which was associated with decrease in D2R in striatum
by some investigators, are more vulnerable to addictive
behaviors such as compulsive food intake and are more likely
to be obese [38, 39]. Leptin receptors are also present in the
ventrotegmental area (VTA) and leptin targets dopaminergic
and gammaaminobutyric acid neurons in this region critical
to brain reward circuits, inducing phosphorylation of signal
transducer and activator of transcription. Direct adminis-
tration of leptin in the VTA causes decreased food intake
[40, 41].
In humans, DA metabolite concentrations in the CSF
decrease as leptin increases which could reﬂect inhibition of
DA release by leptin. Indeed, preclinical studies have shown
that short-term leptin treatment decreases both DA release
and concentration in NAc (nucleus accumbens) and
hypothalamus in a dose-dependent manner [41–43]. How-
ever, it is postulated that leptin may exert at least part of its
inﬂuence through a pathway linked to H1-receptor, reducing
food intake [44]. In fact leptin-induced food intake appears
suppressed in H1 knockout mice [45, 46]. This data suggests
thathypothalamichistamineisamodulatorofleptinactivity.
Hence, it is conceivable that antipsychotic drugs with a
high aﬃnity for H1-receptors could disarrange this pathway,
inducing or exacerbateing a resistance to leptin action.
Beside the very rare case of genetic leptin deﬁciency, the
vast majority of obese humans have high plasma leptin con-
centrations related to the size of adipose tissue. However,
thiselevatedleptinsignaldoesnotinduceexpectedresponses
(i.e., a reduction in food intake and an increase in energy
expenditure), thus suggesting that most obese human sub-
jects are resistant to the eﬀects of endogenous leptin [47].
Thereis some evidencein regardofa“suppressor of cytokine
signaling-3” (SOCS-3) that could act as an inhibitor of leptin
signaling [48, 49]. High leptin levels could determine an
increaseofSOC-3thatmayinturnleadtoresistancetoleptin
action [49].
Thus, leptin has been intensively investigated with
respect to its association with changes in weight and glucoseJournal of Obesity 3
metabolism during treatment with various antipsychotics
(APs). In that regard, our team reviewed longitudinal and
cross-sectional studies which evaluated the eﬀects of AP
on leptin concentration, in addition to literature assessing
genetic factors causing risk for ﬂuctuations in leptin levels
and risk for weight gain in response to AP treatment.
2. ClozapineTreatment
Clozapine has been a major focus of this research. Bromel
et al. (1998) [50] evaluated serum leptin levels (SLLs) in
12 patients (9 schizophrenic and 3 schizoaﬀective disorder
patients)inclozapinetreatment.Inthisstudy,only8patients
were additionally treated with conventional neuroleptics and
other psychotropic drugs. The authors reported that after
clozapine treatment, patients’ SLLs diﬀered signiﬁcantly
from levels measured afterward (P<. 0001), with concen-
trations at least doubling in 8 clozapine-treated psychotic
patients, acutely evaluated (week 2) versus baseline, and no
signiﬁcant changes in more chronic treatment (up to the
10th week versus week 2). The net diﬀerences in BW and
body mass index (BMI) between baseline at week 2 revealed
positive correlations to the relative increases in the SLL.
Kivircik et al. (2003) found that the analysis of variance on
19 clozapine-treated schizophrenic in- and outpatients who
completed 10 weeks of treatment did not reveal any signif-
icant change in plasma leptin levels (PLLs), however, they
reported that the patient gained 5% of their BW, with a
signiﬁcant increase in BMI [51].
Theisen et al. (2005) investigated SLL and BMI in 12
clozapine treated patients with schizophrenia or schizoaﬀec-
tive disorders over a 10-week drug assumption (8 patients
were additionally treated with other AP, benzodiazepines,
and/or antidepressant). The investigators observed that both
SLL and BMI increased signiﬁcantly from baseline [52].
Long-term treatment with clozapine and conventional
APs has been studied in a longitudinal study by Hagg et al.
(2001) [53]. They compared 41 schizophrenic patients in
treatment with clozapine over approximatley 2.8 years with
62 taking conventional over the course of about 8.7 years.
The authors reported an increase of PLL signiﬁcantly associ-
ated with clozapine treatment in both men and women, but
an increase in leptin levels with conventional AP treatment
only in men.
Furthermore, Monteleone et al. (2002) found that a sig-
nificant increase in circulating leptin may be a predictive
factor for weight gain after clozapine treatment [54].
3.OlanzapineTreatment
Studies on olanzapine treatment have some mixed ﬁndings,
but an increase in leptin levels has generally been observed.
Graham et al. (2003) evaluated SLL levels at baseline, and
again after 12 weeks, in nine ﬁrst-episode psychosis patients.
They did not observe any signiﬁcant variation in SLL levels.
However, they did ﬁnd signiﬁcant variation in BW [55]. On
the other hand, Murashita et al. (2005) compared meta-
bolic parameters before and after 6-month treatment with
olanzapine in seven Japanese patients with schizophrenia.
They found that the SLLs were signiﬁcantly increased, but
BW and BMI did not vary signiﬁcantly after 6 months of
treatment [56]. Hosojima et al. (2006) recruited 13 patients
with schizophrenia in monotherapy with olanzapine for 4
weeks [57]. As seen in previous studies, SLL increased from
baseline to week 4. These changed in leptin levels appear to
be quite rapid, and Wang et al. (2006) were the ﬁrst to report
these very early changes in leptin levels. They found a rapid
increment in the PLLs at the fourth hour after the beginning
of the olanzapine treatment in 9 schizophrenic patients. This
increment stayed stable in week 2 [58].
Interestingly, Pe˜ na et al. (2008) observed a signiﬁcant
incrementinSLLatweek8butnotinweek16versusbaseline
in a sample of 60 olanzapine-treated patients after a switch
from typical antipsychotics. They did, however, ﬁnd a sig-
niﬁcant weight gain (WG) and BMI increase that paralleled
leptin levels at week 8 [59]. Popovic et al. (2007) evaluated
the modiﬁcations of SLL in 13 clozapine or risperidone-
treated schizophrenic patients switched by conventional AP
during 12 weeks [60]. A signiﬁcant increase in SLL was
observed at week 12. However, leptin concentrations in 18
patients treated with conventional AP were not diﬀerent as
compared with 20 healthy controls. In a longitudinal study,
Ederetal.(2001)observedaconcomitantsigniﬁcantincrease
in SLL over baseline and olanzapine-induced WG over
baselineduringan8-weekperiodinschizophrenicinpatients
(n = 10), assigned to monotherapy with olanzapine and
compared with healthy subjects [61]. Similarly, Atmaca et al.
(2007) evaluated schizophrenic patients (n = 21), enrolled
in olanzapine monotherapy during 6 weeks, and compared
with healthy controls (n = 21) [62]. These investigators
reportedthatleptinlevelswereincreasedfromthebaselinein
the patients, while no diﬀerence was observed in the control
group during the same period. In addition, the mean change
in BW in the olanzapine group correlated with the change in
leptin levels and in BMI [62].
The changes observed in leptin levels with regard to
treatment with olanzapine have been seen as signiﬁcantly
varied in comparison to treatment with other APs. For ex-
ample, a longitudinal study by Atmaca and collegues (2003),
compared 45 patients with schizophrenia, treated by mon-
otherapy with either quetiapine (n = 15), olanzapine (n =
15), or haloperidol (n = 15) [63]. The patients were eval-
uated at baseline and after 6 weeks of medication. These
authors found a marked increase in leptin levels for the
olanzapine versus the quetiapine group and for the olanza-
pine versus the haloperidol group. In addition, Kraus and
colleagues (1999) measured PLLs, weight, and BMI at base-
lineandweekly(over4weeks)inpatientswithschizophrenia
who received clozapine (n = 11), olanzapine (n = 8), or
treatment with haloperidol (n = 13), and in another group
of patients receiving no pharmacological treatment (n = 12)
[64]. They observed an early increase (at the end of the
ﬁrst week) of PLL associated with olanzapine and clozapine-
induced WG. In contrast leptin levels, weight, and BMI
remained stable in patients receiving haloperidol or no
pharmacological treatment.4 Journal of Obesity
4. Treatment withOther Atypicaland
TypicalAntipsychotics
Zhang et al. (2003) evaluated the eﬀects of risperidone and
chlorpromazine on leptin, insulin secretion, and fat deposi-
tion, in 46 schizophrenic patients [65]. These authors have
found a signiﬁcant elevation in PLL after 10 weeks of med-
ication, with signiﬁcant interactions with gender. In their
study, Herran et al. (2001) evaluated the eﬀects on SLL of
long-term typical and atypical antipsychotic treatment (at
least 6 months) of 59 schizophrenic outpatients compared
with59healthycontrols[66].Diﬀerencesinleptinlevelswere
signiﬁcant in patients treated with atypical antipsychotics
with gender eﬀect (levels were higher in females). The
authors have also noted that SLL in patients correlated
signiﬁcantly with WG and showed a trend for an association
with BMI gains. Haupt and colleagues have pointed out no
evidence of modulation of plasma leptin concentration by
typical or atypical antipsychotics (olanzapine, risperidone)
in 72 schizophrenic patients [67].
5. PreclinicalResearch
The ﬁndings in human studies are inconsistent with results
fromanimalmodelsandinvitrostudies.Intheirexperiments
treating mature adipose cells from human mammary tissue
with clozapine, Hauner et al. (2004) did not ﬁnd any var-
iations in insulin-stimulated glucose transport or leptin
production [68]. Consistently, Cooper et al., (2008) using
an animal model, performed a 20-day ﬁxed-dosed treatment
using 1, 2, or 4mg/kg/day olanzapine in female rats, and did
not ﬁnd any signiﬁcant diﬀerences across any of the cohorts
in serum leptin levels at endpoint despite diﬀerences in
weight gain [69]. On the other hand, Sondhi et al. (2006)
found increases in serum leptin levels after 28 days of
clozapine treatment in rats [70].
6.GeneticandPharmacogenetic Studies
To our knowledge, rare mutations in leptin gene (LEP) and
LeptinReceptorgene(LEPR)causemorbidobesityinstudies
using both human subjects or animal models. Several studies
have shown modest eﬀects of rs7799039 LEP (−2548G/A
functional polymorphism) and rs1137101 LEPR variants on
BMI, and some research has associated the same polymor-
phisms with antipsychotic-induced weight gain, with some
inconsistent results.
The ﬁrst of these studies by Yang et al. (2007) examined
the −2548G/A functional polymorphism in the leptin gene
promoter [71]. This promoter region polymorphism is
reported to inﬂuence the secretion of leptin which is asso-
ciated with obesity. The authors found that homozygosity
for this polymorphism was signiﬁcantly associated with
antipsychotic-inducedweightgain.Thesamepolymorphism
(−2548G/A polymorphism) was investigated by Templeman
etal.(2005)ina9-monthstudyofneuroleptic-na¨ ıvepatients
with schizophrenia from Spain (n = 73). The authors found
that the polymorphism was associated with weight gain
over the 9-month period. The same population has been
scrutinized for a 5-HT2C receptor association. Data from
the combined leptin and 5-HT2C −759C/T genotype eﬀect
reported by Templeman et al. (2005) indicates that this ge-
netic variability can account for over 25% of the variance in
weight gain. The same team also showed that the 5-HT2C
polymorphism, like the leptin polymorphism, inﬂuences
leptin secretion [72]. On the other hand the −759T allele
showed a protective eﬀect and resulted in higher plasma
leptin prior to treatment. These ﬁndings suggest a pharma-
cogenetic inﬂuence of leptin gene polymorphisms in antip-
sychotics-induced weight gain.
Perez-Iglesias et al. (2010) studied patients (n = 205)
who received either haloperidol, olanzapine, risperidone, zi-
prasidone, aripiprazole, or quetiapine treatment (all antipsy-
chotic treatments were adjusted to the lowest eﬀective
dosage), and who were genotyped for rs7799039 LEP and
rs1137101 LEPR, but no signiﬁcant association with BMI or
with antipsychotic-induced weight gain was found [73]. As
well, the LEPR gene has been investigated by Moons et al.
(2010)whohavedoneanassociationstudytoexaminepossi-
ble association between LEPR polymorphism rs8179183 and
several body parameters in 261 schizophrenia or schizoaﬀec-
tive patients treated typical or atypical antipsychotics with
no signiﬁcant results [74]. Fernandez et al. (2010) conducted
a study in clozapine-treated patients who entered a trial to
assess the eﬀect of metformin, an antidiabetic medication
[75].Clinicalandpreclinicalﬁndingssuggestthatmetformin
aﬀects leptin synthesis and serum levels and enhances leptin
and insulin sensitivity. In this study, they ﬁrst evaluated
the frequency of the metabolic syndrome and obesity,
anthropometric and biochemical variables before and after
randomization, and subsequently compared diﬀerences in
BW among genotypes (LEP −2548G/A and Q223R LEPR).
No association was observed between the leptin system pol-
ymorphisms and the anthropometric variables during treat-
ment with metformin or placebo. The QQ LEPR genotype
hasdisplayedsigniﬁcantlylowertriglyceridelevelsatbaseline
and showed some of the expected response to metformin.
In constrast, the GG LEP genotype has showed a signiﬁcant
increase in glucose after treatment with metformin [75].
Gregoor et al. (2009) performed a cross-sectional analysis
to determine whether the LEPR Q223R polymorphism and
the LEP promoter −2548G/A polymorphism are associated
with obesity and atypical AP treatment [76]. No signiﬁcant
association was found between LEP promoter −2548G/A
polymorphism and obesity, while in females, but not in
males, the LEPR 223QR and LEPR 223RR genotypes were
associated with lower risk of obesity. Srivastava et al. (2008)
found that the rs4731426 SNP, a variant in the leptin gene,
was moderately associated with median weight gain and
signiﬁcantly associated with extreme weight gain in North
India subjects in olanzapine treatment [77]. Leptin has been
investigated also by Ellingrod et al. (2007) in a phar-
macogenetic association reanalysis of a longitudinal open
label ﬁxed-dose trial of olanzapine response and adverse
eﬀects [78] .T h ee n r o l l e ds u b j e c t sw e r eg e n o t y p e df o rt h e
−2548G/A polymorphism of the leptin gene and the Q223R
polymorphism of the leptin gene receptor. Genotypes were
not individually associated with olanzapine-induced weightJournal of Obesity 5
gain. Changes in weight from baseline increased signiﬁcantly
inpatientscarryingatleastoneGalleleatbothcandidateloci
and high olanzapine plasma levels.
7. Conclusions
A majority of research has focused on the eﬀects of clozapine
and olanzapine on SLL. The positive modulation of this
parameter by the studied atypical antipsychotics has been
observed as early as a few hours after the beginning of the
treatment, peaking between 6 and 10 weeks after, and re-
maining elevated for a period of up to several months. With
respect to atypical AP treatment, a number of studies found
elevated leptin levels following atypical AP medications, in
some cases independent of BMI increase.
It is relevant to note that while weight gain with olanza-
pine and clozapine therapy predominantly occurs over the
ﬁrst 6 months of treatment plateauing after 6 months to 1
year of treatment, leptin changes do not parallel with weight
changes during extended AP treatment as pointed out by
Bromeletal.[50].ThispatternwasreplicatedbyMonteleone
et al. (2002) [54], and Theisen et al. (2005) [52]i nl a t e r
studies. In contrast to olanzapine and clozapine, ﬂuctuations
in SLL have not been seen in risperidone treatment, which
is consistent with the conventional neuroleptic treatment
causing less ﬂuctuation in BW.
Weight gain as a result of AP treatment is associated
with signiﬁcant physical and psychological morbidity, and
patients undergoing AP treatment have signiﬁcant and valid
concerns about weight gain and weight management. Sub-
stantial progress has recently been made in understanding
weightgain,energyexpenditurerate,andchangesinappetite
associated with AP treatment, including the identiﬁcation
of markers of obesity risk caused by ﬂuctuation in energy
homeostasis, metabolic variation, and energy intake and
expenditure during antipsychotic treatment. Among these
markers,leptincouldplayanimportantroleandisassociated
with weight gain in atypical antipsychotic treatment as seen
in the present review.
Although it is true that these changes can be explained
by adiposity, and produced and released by adipocytes in
response to increased fat deposition to regulate body weight,
there is intriguing evidence to support the hypothesis that
antipsychotics could induce or exacerbate a leptin-resistance
status. Resistance to leptin could generate metabolic condi-
tions resulting in weight gain. Further research is still needed
to clarify the relationship between leptin and antipsychotics.
The elucidation of these potential mechanisms could be
important for quantiﬁcation of patient risk during treatment
with antipsychotics and can spur development of novel
forms of treatment.
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